Resources

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is an innovative injectable contraceptive that can dramatically expand access and choice for women. The following collection of resources provides an overview of research and experience on the feasibility and acceptability of DMPA-SC among family planning clients and providers. For more information, visit www.path.org/dmpa-sc or email FPoptions@path.org.

This brief outlines the current state of immunization in Uganda and the efforts, investments, and strategies required to meet the commitments made in the Addis Declaration on Immunisation and ensure all Ugandans receive the promise of immunisation.

This case study examines the use of advocacy for increased misoprostol access in Nigeria, specifically the market-based approach taken by PATH and the Generation Initiative for Women and Youth network to design an initiative for increasing public-sector use of the drug.

This case study examines the use of advocacy to reduce newborn infections in Bangladesh, specifically the market advocacy efforts by PATH and the Bangladesh Pediatric Association to engage public and private stakeholders to understand the importance of 7.1 percent chlorhexidine digluconate use.

This fact sheet describes PATH’s work to increase access to oxygen therapy for the treatment of life-threatening pneumonia and hypoxemia in newborns and children. Facilitating inclusion of expanded uses of oxygen on the World Health Organization’s Essential Medicines List, as well as the inclusion of oxygen technologies and pulse oximetry in global commodity lists and treatment guidelines, are essential for reducing child mortality.